- Short report
- Open Access
Self-assembly of hexahistidine-tagged tobacco etch virus capsid protein into microfilaments that induce IgG2-specific response against a soluble porcine reproductive and respiratory syndrome virus chimeric protein
© The Author(s). 2016
- Received: 5 July 2016
- Accepted: 17 November 2016
- Published: 29 November 2016
Assembly of recombinant capsid proteins into virus-like particles (VLPs) still represents an interesting challenge in virus-based nanotechnologies. The structure of VLPs has gained importance for the development and design of new adjuvants and antigen carriers. The potential of Tobacco etch virus capsid protein (TEV CP) as adjuvant has not been evaluated to date.
Two constructs for TEV CP expression in Escherichia coli were generated: a wild-type version (TEV-CP) and a C-terminal hexahistidine (His)-tagged version (His-TEV-CP). Although both versions were expressed in the soluble fraction of E. coli lysates, only His-TEV-CP self-assembled into micrometric flexuous filamentous VLPs. In addition, the His-tag enabled high yields and facilitated purification of TEV VLPs. These TEV VLPs elicited broader IgG2-specific antibody response against a novel porcine reproductive and respiratory syndrome virus (PRRSV) protein when compared to the potent IgG1 response induced by the protein alone.
His-TEV CP was purified by immobilized metal affinity chromatography and assembled into VLPs, some of them reaching 2-μm length. TEV VLPs administered along with PRRSV chimeric protein changed the IgG2/IgG1 ratio against the chimeric protein, suggesting that TEV CP can modulate the immune response against a soluble antigen.
- Tobacco etch virus
- Capsid protein
- Virus-like particles
- Hexahistidine tag
- Chimeric protein
The structural proteins of some viruses occasionally mimic the three-dimensional nature of an actual virus while lacking the virus genome packaged inside its capsid . These structures, also called virus-like particles (VLPs), apart from bearing self-assembly properties, feature highly ordered structure and surface repetitiveness, making them good candidates for the development of vaccines and epitope presenting platforms . The upsurge of these applications has driven the cloning, expression and purification of virus structural components in a wide range of host systems (reviewed by Zeltins ). However, in most cases the self-assembly of viral capsid proteins (CPs) into VLPs still remains a challenge .
We previously attempted to explore the potential of Tobacco etch virus (TEV) particles as an adjuvant and our findings suggested that TEV induce both humoral and cellular response without the need of any other stimulus . However, the use of plant viral infectious particles poses additional safety and environmental challenges . By 1990s, research on Johnson grass mosaic virus (JGMV) CP led to propose the use of chimeric potyvirus-like particles for epitope carrying or display taking advantage of particle features, as reviewed by Jagadish and others . For the first time, Jagadish and others  successfully expressed in a recombinant system (E. coli) the JGMV CP that assembled into virus-like particle structures. Since then, the list of VLP assembly from E. coli-expressed potyviral CPs has been extended to Potato virus Y (PVY) , Plum pox virus , Pepper vein banding virus , Papaya ringspot virus  and TEV . Interestingly, none of these potyviral CPs were expressed as a fusion to a Histidine tag, perhaps based on the rationale that this tag would compromise CP self-assembly. In the current report we investigated whether TEV CP VLPs can be assembled from Histidine-tagged TEV CP, produced and purified at high level from E. coli cultures. We also evaluated the potential use of TEV CP VLPs as an adjuvant for a novel porcine respiratory and reproductive syndrome virus (PRRSV) chimeric protein.
For obtaining VLPs from TEV CP soluble non-tagged version, lysates were treated with 4% (w/v) PEG 8000 for 1.5 h at 4 °C with constant shaking and left for 1 h at room temperature (22 ± 2 °C). Then, the sample was centrifuged at 4 °C, for 20 min, at 2,370 × g and the precipitate was solubilized overnight in 10 mM Tris-HCl buffer, 300 mM NaCl, 10 mM EDTA, pH 7.4. Samples were centrifuged at 4 °C, for 20 min, at 2,370 × g and VLP-enriched supernatants were passed through a 100 kDa MWCO Amicon Ultra-4 filtration centrifugal unit (Merck-Millipore, Germany). The estimated yield of this non-tagged version was 1.2 mg/l of culture, as assessed by densitometric analysis, due to presence of several proteins belonging to the expression host that also precipitated with PEG. On the other hand, the His-tagged version was purified by Ni2+ affinity chromatography. Analysis of purification fractions showed recovery of partially purified His-TEV-CP protein (Fig. 1b). Larger and shorter forms of TEV CP were observed in purified preparations of His-TEV-CP version, which might correspond to dimers and proteolysis byproducts, respectively (Fig. 1c). The yield of purified TEV CP was calculated at 10 mg/l of culture, as estimated using Bradford reagent against a BSA curve. Final preparations were stable for months when maintained at 4 °C in matrix buffer (see Fig. 1 legend) with 500 mM NaCl.
Most of the research in VLP production and assembly has been focused in plant viruses with isodiametric symmetry, like Cowpea mosaic virus and Cowpea chlorotic mottle virus, the rigid rods of Tobacco mosaic virus (TMV) and the filamentous particles of Papaya mosaic virus (PapMV) . The production of TEV CP VLPs has been previously accomplished in a previous work , where particles ranging from 90 to 750 nm in length were observed, but level of expression was not reported. Furthermore, the assembly of His-tagged versions of TEV CP into VLPs was not addressed, in contrast to the results shown here. There are two factors that can explain these disparate results: the plasmids used for expressing His-tagged TEV CP versions and expression levels. The previous work describes the use of a plasmid (pTrcHis B from Thermo Fisher Scientific, USA) that adds at least 35 amino acids, including the His-tag, to the N-terminus of the recombinant protein, compromising VLP formation, while the plasmid used in the present work (pET28a + from Merck-Millipore, Germany) just adds 8 amino acids to TEV CP, leaving VLP assembly unaffected. Regarding the non-tagged versions, it is possible that the expression levels of TEV CP in the previous report reached the minimum amount required for spontaneous assembly, which was not the case in the present work. We hypothesized that His-tagged TEV CP, expressed at moderately higher levels than its non-tagged counterpart, must have been assembled right after the elution step of Ni2+ affinity chromatography. This could explain why a few VLPs were observed by TEM when analyzing His-tagged TEV CP samples before purification (Fig. 2a), however, additional experiments must be carried out in order to confirm this hypothesis. To our knowledge, there is no work thus far describing the expression of a His-tagged potyviral CP that assembles into VLPs. TMV studies have demonstrated a pivotal role of His-tag on controlling assembly of CP monomers to different virus-like structures, like rings, discs, rods, and filamentous structures [18, 19]. However, despite the potential of affinity tags, like hexahistidine, to facilitate process development of proteins, these may have undesired consequences on protein stability in solution and immunogenicity .
The novel PRRSVchim demonstrated to elicit potent IgG antibody response without the need of any adjuvant. This high immunogenicity is perhaps due to the ability of this chimeric protein to form oligomeric structures, as demonstrated by dynamic light scattering (Additional file 2: Figure S2), revealing the presence of a major peak with a mean diameter of 180 nm. However, the response is restricted to IgG1 subclass. As an unexpected result, this antibody response against PRRSVchim did not increase when the TEV CP VLPs were administered along with, even when different ratios of VLPs were used (Fig. 3). In contrast, TEV CP VLPs induced a change in the IgG2/IgG1 ratio, counteracting the IgG1-polarized antibody response to PRRSVchim protein alone (Fig. 3). In mice, it is well documented that IgG1 is related to Th2 immunity, while IgG2a reflects a Th1 bias. In addition, soluble proteins are generally restricted to the IgG1 isotype, while most antiviral response belongs to IgG2a . PapMV CP nanoparticles administered with trivalent flu vaccine showed an increase in the production of IgG1 and IgG2a against influenza virus . In addition, PRSV CP filamentous particles administered with green fluorescent protein (GFP) induce an increase in GFP-specific IgG1 and the strength of the response depends on the ratio of VLPs used . Based on PRRSVchim antibody response, it appears that TEV CP VLPs have a role in balancing both arms of the immune system, humoral and cellular response, against PRRSVchim. Some authors have mentioned that the success of a PRRSV vaccine relies on its ability to induce both neutralizing epitopes and cellular response . To our knowledge there is no report in the use of TEV CP-based particles, some of them longer than 1 μm, for aiding the immune response against a soluble antigen. Nevertheless, an interesting work by Kalnciema et al. demonstrates the usefulness of PVY microparticles as antigen carriers when translationally fused to foreign sequences of up to 71 amino acids long . Finally, it is becoming evident that the size of the adjuvant may have different effects on the type of the immune response induced; it appears that microparticles promote humoral response, whereas nanoparticles may favor the induction of cellular response . In summary, our results demonstrate that a hexahistidine-tagged TEV CP is successfully purified by Ni2+ affinity chromatography and self-assembles into long VLPs. Also, these particles contribute in balancing the immune response elicited by a novel chimeric protein comprising sequences from a swine virus, which in turn is a potent immunogen per se. The immune response of swine immunized with these TEV CP VLPs/PRRSVchim formulations needs to be investigated. These findings highlight the potential of TEV CP VLPs as particulate adjuvants with immune modulation properties without the need of antigen’s attachment.
The authors wish to acknowledge Sirenia González Pozos for technical support with the transmission electron microscopy at Laboratorio Avanzado de Nanoscopía Electrónica, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Unidad Zacatenco. The scholarship to CAMC from CONACyT is gratefully acknowledged.
This work was supported by Fondo Sectorial de Innovación Secretaría de Economía-CONACYT (FINNOVA) project 238667.
Availability of data and materials
CAMC performed the experiments, analyzed the data and drafted the manuscript. AVC helped in preparing the samples for TEM. EPC and RHG designed and performed the immunization procedures. SEHR designed and performed ELISA test and helped to draft the manuscript. AGO conceived and designed the experiments, help in drafting the manuscript and supervised the work. All of the authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Mice experimentation protocol was approved by the Internal Committee for the Care and Use of Laboratory Animals of Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (reference number 2015-006).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Vicente T, Roldão A, Peixoto C, Carrondo MJT, Alves PM. Large-scale production and purification of VLP-based vaccine. J Invertebr Pathol. 2011;107:S42–8.View ArticlePubMedGoogle Scholar
- Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. J Biol Chem. 2008;389(5):521–36.Google Scholar
- Zeltins A. Construction and Characterization of Virus-Like Particles: A Review. Mol Biotechnol. 2013;53:92–107.View ArticlePubMedGoogle Scholar
- Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: Platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(2):174–96.View ArticlePubMedGoogle Scholar
- Manuel-Cabrera CA, Márquez-Aguirre A, Rodolfo HG, Ortiz-Lazareno PC, Chavez-Calvillo G, Carrillo-Tripp M, Silva-Rosales L, Gutiérrez-Ortega A. Immune response to a potyvirus with exposed amino groups available for chemical conjugation. Virol J. 2012;9:75.View ArticlePubMedPubMed CentralGoogle Scholar
- Lebel M-E, Chartrand K, Leclerc D, Lamarre A. Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants. Vaccines. 2015;3:620–37.View ArticlePubMedPubMed CentralGoogle Scholar
- Jagadish MN, Edwards SJ, Hayden MB, Grusovin J, Vandenberg K, Schoofs P, Hamilton RC, Shukla DD, Kalnins H, McNamara M, Haynes J, Nisbet IT, Ward CW, Pye D. Chimeric potyvirus-like particles as vaccine carriers. Intervirology. 1996;39(1-2):85–92.PubMedGoogle Scholar
- Jagadish MN, Ward CW, Gough KH, Tulloch PA, Whittaker LA, Shukla DD. Expression of potyvirus coat protein in Escherichia coli and yeast and its assembly into virus-like particles. J Gen Virol. 1991;72:1543–50.View ArticlePubMedGoogle Scholar
- Stram Y, Sela I, Edelbaum O, Tanne E, Karchi M, Karchi H. Expression and assembly of the potato virus Y (PVY) coat protein (CP) in Escherichia coli cells. Virus Res. 1993;28:29–35.View ArticlePubMedGoogle Scholar
- Jacquet C, Delecolle B, Raccah B, Lecoq H, Dunez J, Ravelonandro M. Use of modified plum pox virus coat protein genes developed to limit heteroencapsidation-associated risks in transgenic plants. J Gen Virol. 1998;79(Pt 6):1509–17.View ArticlePubMedGoogle Scholar
- Joseph J, Savithri HS. Determination of 3′-terminal nucleotide sequence of pepper vein banding virus RNA and expression of its coat protein in Escherichia coli. Arch Virol. 1999;144(9):1679–87.View ArticlePubMedGoogle Scholar
- Chatchen S, Jurícek M, Rueda P, Kertbundit S. Papaya Ringspot Virus Coat Protein Gene for Antigen Presentation in Escherichia coli. J Biochem Mol Biol. 2006;39(1):16–21.PubMedGoogle Scholar
- Voloudakis E, Malpica CA, Aleman-Verdaguer ME, Stark DM, Fauquet CM, Beachy RN. Structural characterization of Tobacco etch virus coat protein mutants. Arch Virol. 2004;149:699–712.View ArticlePubMedGoogle Scholar
- Guerrero-Rodríguez J, Manuel-Cabrera CA, Palomino-Hermosillo YA, Delgado-Guzmán PG, Escoto-Delgadillo M, Silva-Rosales L, Herrera-Rodríguez SE, Sánchez-Hernández C, Gutiérrez-Ortega A. Virus-Like Particles from Escherichia coli-Derived Untagged Papaya Ringspot Virus Capsid Protein Purified by Immobilized Metal Affinity Chromatography Enhance the Antibody Response Against a Soluble Antigen. Mol Biotechnol. 2014;56(12):1110–20.View ArticlePubMedGoogle Scholar
- Kalnciema I, Balke I, Skrastina D, Ose V, Zeltins A. Potato Virus M-Like Nanoparticles: Construction and Characterization. Mol Biotechnol. 2015;57(11-12):982–92.View ArticlePubMedGoogle Scholar
- Willson RC, Murphy JC. Nucleic acid separation using immobilized metal affinity chromatography. US patent publication number US. 2004;20040152076:A1.Google Scholar
- Visciano ML, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L. Effects of adjuvants on IgG subclasses elicited by virus-like particles. J Transl Med. 2012;10(4):1–8.Google Scholar
- Bruckman MA, Soto CM, McDowell H, Liu JL, Ratna BR, Korpany KV, Zahr OK, Blum AS. Role of Hexahistidine in Directed Nanoassemblies of Tobacco Mosaic Virus Coat Protein. ACSNano. 2011;5(3):1606–16.Google Scholar
- Ratna BR, Blum AS, Soto CM, Bruckman MA, Liu JL, Rendell RW, Long JP, Tonucci RJ. Metamaterial optical elements self-assembled on protein scaffolds. US patent publication number US. 2014;20148831386:B2.Google Scholar
- Khan F, Legler PM, Mease RM, Duncan EH, Bergmann-Leitner ES, Angov E. Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice. Biotechnol J. 2012;7(1):133–47.View ArticlePubMedGoogle Scholar
- Markine-Goriaynoff D, van der Logt JT, Truyens C, Nguyen TD, Heessen FW, Bigaignon G, Carlier Y, Coutelier JP. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. Int Immunol. 2012;12(2):223–30.View ArticleGoogle Scholar
- Savard C, Guérin A, Drouin K, Bolduc M, Laliberté Gagné M-E, Dumas MC, Majeau N, Leclerc D. Improvement of the trivalent inactivated Flu vaccine using PapMV nanoparticles. PLoS One. 2011;6(6), e21522.View ArticlePubMedPubMed CentralGoogle Scholar
- Yu M, Qiu Y, Chen J, Jiang W. Enhanced humoral and cellular immune responses to PRRS virus GP5 glycoprotein by DNA prime-adenovirus boost vaccination in mice. Virus Genes. 2016;52(2):228–34.View ArticlePubMedGoogle Scholar
- Kalnciema K, Skrastina D, Ose V, Pumpens P, Zeltins A. Potato Virus Y-Like Particles as a New Carrier for the Presentation of Foreign Protein Stretches. Mol Biotechnol. 2012;52(2):129–39.View ArticlePubMedGoogle Scholar
- Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010;9(9):1095–107.View ArticlePubMedPubMed CentralGoogle Scholar